Worldwide at least 200 per 100 000 people are killed or admitted to hospital each year after traumatic brain injury. 1 This results in more than 10 million deaths or hospital admissions. 2 In the UK, around one million people attend emergency departments every year with a traumatic brain injury. 3
Intracranial bleeding is common after traumatic brain injury, and the larger the bleed the greater the risk of death and disability. 4 5 Bleeding continues after hospital admission in 84% of patients with moderate or severe injuries, 6 7 and can continue for up to 24 hours. 8 About one third of patients have laboratory evidence of abnormal coagulation. 9 High levels of fibrin degradation products are seen within the first three hours. 10 Such patients have a higher risk of intracranial haemorrhage and mortality.
Tranexamic acid reduces bleeding by inhibiting the enzymatic breakdown of fibrin blood clots ( fig 1⇓) .
Tranexamic acid is used routinely in some cases of trauma and in surgery. For example, it reduces the need for blood transfusion in surgical patients. 11 12 In trauma patients with extracranial haemorrhage: 13 • Tranexamic acid treatment within an hour of injury reduces the risk of death caused by bleeding by about one third (5.3% tranexamic acid v 7.7% placebo relative risk 0.68, 95% confidence interval 0.57 to 0.82; P<0.001);
• treatment between one and three hours reduces the risk by about one fifth (4.8% v 6.1%; 0.79, 0.64 to 0.97; P=0.03);
• there is no apparent benefit after three hours, and tranexamic acid might even be harmful (4.4% v 3.1%; 1.44, 1.12 to 1.84; P=0.004). 14 If tranexamic acid is effective after traumatic brain injury, it should also be most effective when given soon after injury, when intracranial bleeding is ongoing. 8 The potential for harm also exists however.
• Tranexamic acid may increase the risk of ischaemia and cerebral thrombosis because it inhibits fibrinolysis. 15 Cerebral ischaemia is already a known risk after after traumatic brain injury, which worsens neurological outcome and increases mortality. 16 17 For example, raised intracranial pressure can lead to cerebral hypoperfusion. [18] [19] [20] Thrombotic disseminated intravascular coagulation might increase the risk of cerebral microthrombi, which are often seen in the brains of patients with traumatic brain injury who have died. 21
• Seizures are also a risk because tranexamic acid is known to cross the blood-brain barrier. 22 Although there was no evidence of any increase in seizures in the CRASH-2 trial of tranexamic acid in extracranial bleeding, seizure activity remains a concern because the blood-brain barrier is impaired after traumatic brain injury. 23
What is the evidence of uncertainty?
A 2015 systematic review identified two relevant completed randomised trials (table 1⇓) . 24 25 We judged that both trials were at low risk of bias; however, neither was large enough to answer the question definitively-the confidence intervals were wide and the P values statistically insignificant. The first trial (n=249) examined the effect of tranexamic acid in patients with extracranial bleeding but who also had traumatic brain injury. 24 The second trial (n=229) examined the effect of tranexamic acid in patients with polytrauma and traumatic brain injury, or isolated traumatic brain injury. 25 Both trials recruited patients who were within eight hours of injury but the numbers were not large enough to determine the balance of risks and benefits from tranexamic acid and whether this varies by time to treatment. Furthermore, the patients in one of the trials had The review authors rated the quality of the evidence according to the GRADE approach and considered: impact of the risk of bias of individual trials; precision of the pooled estimate; inconsistency or heterogeneity; indirectness of evidence; and impact of selective reporting and publication bias on effect estimate. Risk of bias was assessed using the Cochrane Collaboration's "risk of bias" tool.
As the last update was published in May 2015, we reran the search to identify no new completed trials and one new pending trial (NCT02645552).
extracranial bleeding in addition to intracranial bleeding. 24 Because tranexamic acid reduces mortality in extracranial bleeding (CRASH-2), the mortality reduction seen in this trial could be from the extracranial injury rather than any effect on the brain injury itself.
When the two randomised trials are combined in a meta-analysis ( fig 2⇓) , there is a statistically significant reduction in intracranial haemorrhage, but because the confidence intervals are wide, the quality of this evidence is low.
• Intracranial haemorrhage-relative risk 0.75 (95% confidence interval 0.58 to 0.98); P=0.03;
• Mortality-relative risk 0.63 (95% confidence interval 0.40 to 0.99); P=0.05.
The effect of tranexamic acid on disability and thrombotic adverse effects including stroke remains uncertain.
Is ongoing research likely to provide relevant evidence?
We identified three ongoing randomised trials of tranexamic acid versus placebo in patients with isolated traumatic brain injury (table 2⇓ ). These will evaluate the effect of tranexamic acid on death, disability, vascular occlusive events, and other adverse events in traumatic brain injury. The ongoing trials inform whether tranexamic acid can be given to those with traumatic brain injury.
In two of the ongoing trials (n=1402) patients are randomised within two hours of injury in the prehospital setting (NCT02645552, NCT01990768).
In the largest trial, the CRASH-3 trial (n=13 000), patients will be randomised in hospital and within eight hours of injury (NCT01402882). 26 The size of this trial should ensure that tranexamic acid and placebo groups are similar for known and unknown confounders, such as the concomitant degree of coagulopathy. 27 Therefore, it is unnecessary to standardise tranexamic acid and placebo groups for clinical management factors that may influence the extent of bleeding.
The results from the three ongoing trials should provide clinicians with information about whether the effect of tranexamic acid varies by time to treatment. Information on the effect of tranexamic acid administered within one hour, between one and three hours, and after three hours of injury may be more useful than the average effect of the treatment. Prespecified subgroup analyses in the CRASH-3 trial will provide information about the effect of tranexamic acid by time to treatment.
A substudy conducted within the CRASH-3 trial will use computed tomography scans to examine the effect of tranexamic acid on intracranial bleeding and thrombosis. These scans can detect traumatic haemorrhage (high attenuation) in the acute stage of traumatic brain injury. Ischaemic lesions (low attenuation) are visible on a computed tomography scan done several hours after injury. This substudy will provide information on the effect of tranexamic acid on intracranial haemorrhage and ischaemia and whether this varies by time to treatment.
Further research
Randomised trials looking at the effect of tranexamic acid in patients with isolated traumatic brain injury are currently ongoing. These trials will address the uncertainty of whether tranexamic acid improves outcomes in patients with traumatic brain injury. At this stage we do not make recommendations for further research in this area.
What should we do in light of the uncertainty?
The authors recommend that patients with isolated traumatic brain injury should not receive tranexamic acid outside the context of a randomised trial, and clinicians should consider enrolling their patients in one of the relevant trials wherever possible.
Box 3 signposts other aspects of management of traumatic brain injury.
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Box 3: Guidelines for general management of traumatic brain injury
The National Institute for Health and Care Excellence provides guidance on the assessment and early management of adults and children with traumatic brain injury. 28 The key recommendations are to:
• First treat the greatest threat to life and avoid further harm by assessing Airway, Breathing, and Circulation The Centers for Disease Control and Prevention and the American College of Emergency Physicians provide guidance on the management of adults with mild traumatic brain injury. 29 The guidelines focus on determining whether patients with known or suspected mild traumatic brain injury require a computed tomography scan of the brain or may be safely discharged.
How patients were involved in the creation of this article
No patients were involved in the writing of this article.
Patients are involved in the design and conduct of CRASH-3. Focus groups were conducted with young men at a boxing club who were at risk of traumatic brain injury, to seek their views on consent procedures; and these were reflected in the trial procedures. Organisations such as the European Federation of Road Traffic Victims, and RoadPeace, the UK national charity for road crash victims, advised the investigators on outcome measures that matter most to patients, such as fatigue. Organisations also represent patients on the trial steering committee and are involved in the ongoing supervision of the trial. 
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